Imaging, QoL and Patient-Reported Outcome and Supportive Care
Category: Imaging, QoL and Patient-Reported Outcome and Supportive Care
Challenges in Diagnosis, Treatment Access, and Quality of Life Among Newly Diagnosed Multiple Myeloma Patients in India: Findings from a Prospective Observational Study" Incidence and Risk Factors of Thromboembolic Events in Chinese Patients with Multiple Myeloma: A Single-Center Retrospective Cohort Study The HSCT-BIOME Study: double-blinded, randomized, placebo-controlled trial using orally-administered, lyophilized faecal microbiota transplantation to prevent HSCT-associated complications Performance of Deauville Score and Total Lesion Glycolysis as Response Markers for Multiple Myeloma with Extramedullary Disease Dialysis-dependence is associated with poor prognosis in multiple myeloma: a multicenter retrospective cohort study ASSESSING THE CLINICAL IMPLICATIONS AND PROGNOSTIC VALUE OF LIGHT-CHAIN N-GLYCOSYLATION IN 781 MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS Cytokine Dysregulation in Multiple Myeloma: A Comprehensive, Comparative Analysis of Blood and Bone Marrow Profiles Characteristics of Long-Term Survivors in Multiple Myeloma: Exploring Factors for Cure After Extended Folow-Up Serum cholesterol levels demonstrate dynamic changes following autologous hematopoietic stem cell transplantation in patients with multiple myeloma Testing and validating a mass spectrometry based algorithm for response assessment in myeloma Gene-expression-profiling plus integrated multidisciplinary approach to detect new-generation risk-adapted prognostic index in smoldering myeloma and multiple myeloma (GIMPI): a new prognostic score Measurable residual disease (MRD) dynamics reveals a therapeutic vulnerability state for early immunotherapy interception in multiple myeloma (MM) Advancing Soluble BCMA Quantification in Immunotherapy: Analytical Validation of ELLA Versus ELISA for Predicting Toxicity and Response Mass Spectrometry vs. 10-5 MRD Detection by Next-Generation Flow and Sequencing in Multiple Myeloma: Results from the Cassiopeia Clinical Trial Whole Genome Sequencing of cell-free DNA for Assessment of Minimal Residual Disease in High-Risk Smoldering Multiple Myeloma Subclonal and clonal progression of previously characterized mutations and variants of unknown significance (VUS) across a cohort of plasma cell dyscrasia patients The Role of CHIP Mutations in Plasma Cell Dyscrasias: Implications for Clonal Evolution and Risk Stratification Quantitative CD38 Expression and Clinical Response to Anti-CD38 Therapy in Multiple Myeloma: A Retrospective Cohort Analysis Patient Perceptions of MRD Negativity as a Treatment Outcome and Regulatory Endpoint in Multiple Myeloma Comprehensive characterization and pharmacological targeting of stem‐like side population compartment in multiple myeloma Comparative Evaluation of Advanced Serum-Based Techniques for the Sensitive Detection of Monoclonal Proteins in Multiple Myeloma – A Pilot Study Circulating Plasma Cells as an Independent Prognostic Marker in Newly Diagnosed Multiple Myeloma: Clinical Correlation and Immunophenotypic Insights Integrating p53 Protein Expression with Mutation and Copy Number Status Enhances Risk Assessment in Myeloma Verification and optimization of VTE risk stratification system for multiple myeloma in China based on review cohort Revealing Clonal Evolution and Assessing Immune Reconstitution in Multiple Myeloma Using Next-Generation Sequencing-Based Minimal Residual Disease (NGS-MRD) Analysis The new IMS / IMWG consensus risk definition predicts outcomes with daratumumab-based quadruplet regimens for multiple myeloma Minimal Residual Disease Kinetics in Patients with Multiple Myeloma Receiving First Line Treatment and the Association with their Progression-Free Survival; A Retrospective Study of 323 patients Bridging the Gap: Conversion of Siemens N-Latex to Binding Site Freelite for Accurate Multiple Myeloma Diagnosis and Risk Stratification Stem cell autograft minimal residual disease negativity predicts improved outcomes after autologous stem cell transplant for multiple myeloma Towards the identification of novel circulating biomarkers associated with bone disease in multiple myeloma Deciphering Genomic Correlates of Differential Treatment Response Kinetics in Multiple Myeloma Peripheral Blood Clonotypic Mass Spectrometry-Based MRD Stratification Identifies Patients at Increased Risk of Progression After Quadruplet Therapy in NDMM LIGHT CHAIN ESCAPE IN MULTIPLE MYELOMA: A NOT-SO-UNUSUAL PHENOMENON Peripheral Residual Disease (PRD) Monitoring by Clonotypic Mass Spectrometry (EASYM) in patients with Newly Diagnosed Multiple Myeloma 3D telomere profiling of MRD in liquid biopsy as a predictive marker of disease stability or progression Lymphocyte to monocyte ratio at minimal residual disease assessment predicted survival time among myeloma patients in complete response Refining MRD surveillance in multiple myeloma: Predictive insights from ultrasensitive bone marrow analysis ABSOLUTE LYMPHOCYTE COUNT (ALC) ≥1,000 IS AS A SURROGATE OF CAR‑T CELL EXPANSION AND A READILY AVAILABLE BIOMARKER TO PREDICT OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) Detectable peripheral blood measurable residual disease (PBMRD) is strongly associated with early progression in Newly Diagnosed Multiple Myeloma (NDMM) Profiling Minimal Residual Disease with Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Patients Receiving BCMA- or GPRC5D-Targeted Agents Clinical utility of quantitative, mass spectrometry-based EasyM for MRD monitoring in multiple myeloma: Integration with established MRD detection techniques in a pan-Canadian real-world cohort study Utilization and Preferences of MRD Testing for patients with Multiple Myeloma: Insights from a Survey of 251 North American Hematologists and/or Oncologists Identification of a CAR–Derived Clone by NGS-based MRD After Fully Human BCMA CAR T-Cell Therapy in Multiple Myeloma Elevated Non-Clonal Bone Marrow Plasma Cell Fraction at Diagnosis Is Associated with Improved Outcomes in Multiple Myeloma
Rudra Narayan Swain (he/him/his)
fellow
Post Graduate Institute of Medical Education and Research
Multiple myeloma (MM) is a plasma cell malignancy with rising incidence in India, where patients often present at a younger age than in Western populations. Although novel therapies have improved survival, many patients experience delays in diagnosis and face significant barriers to accessing care. This prospective single-center study aimed to identify the causes of diagnostic delays, barriers to treatment access, and assess quality of life (QoL) among newly diagnosed MM (NDMM) patients.
Methods:
Between July 2022 and June 2023, 165 NDMM patients were prospectively enrolled. Structured questionnaires were administered at baseline, capturing sociodemographic details, comorbidities, symptom profile, barriers to healthcare access, and QoL using the EQ-5D-5L tool. Diagnostic delay was categorized based on time from symptom onset to initial medical consultation: < 3 months, 3–6 months, and >6 months. Statistical analyses included descriptive statistics, bivariate tests, and logistic regression to identify predictors of diagnostic delay and QoL impairment.
Results: The median age was 56.7 years (range 28–82), with 63.6% of patients being male. Most resided in rural (61%) or semi-urban areas, and nearly half had comorbidities such as hypertension, diabetes, or cardiovascular disease. Only 12.7% had health insurance, and 42% were unemployed. Presenting symptoms included fatigue (26%), bone pain (22%), and fever (16%), with over 75% reporting multiple symptoms.EQ-5D-5L analysis revealed that pain/discomfort was the most affected domain (mean disutility: 0.126), followed by self-care (0.088) and mobility (0.079). The average EQ-VAS score was 57.8 (SD ±22.3), and the mean EQ-5D index was 0.58 (range -0.92 to 1.00), indicating significant QoL impairment. Patients with diagnostic delays >6 months (n=15) had worse QoL (EQ-VAS 53.2, EQ-5D index 0.52) compared to those diagnosed within 3 months (n=127; EQ-VAS 58.7, EQ-5D index 0.57). Major reported barriers included lack of symptom awareness (82%), psychological hesitation (24%), and logistical issues such as transport or appointment difficulties (18%). While logistic regression did not identify statistically significant predictors of delays >6 months, trends indicated that lower education and lack of health insurance may contribute to delayed presentation. None of the demographic or CRAB features significantly predicts worse EQ-5D index scores
Conclusions: Diagnostic delays and reduced QoL remain prominent issues in the management of MM in India. A lack of awareness and psychosocial barriers contribute significantly to delayed presentation. Targeted educational interventions and the decentralisation of myeloma care services are essential to improve early diagnosis and patient-centred outcomes in the Indian context.